RxDoctor Payments Data

Jennifer Dykhouse

Medical · Grand Rapids, MINPI 1881769321

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 438 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,590in general payments, 2019–2025

Across 438 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$968
  • Johnson & Johnson$617
  • E.r. Squibb & Sons, L.L.C.$605
  • Novo Nordisk$474
  • Merck$472
  • Amgen$447
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,31796%
  • Education$2744%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,590 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$281,706
EntrestoSacubitril/Valsartan83$96,158
XareltoRivaroxaban56$51,681
Repatha SureclickEvolocumab35$46,788
JardianceEmpagliflozin40$43,195
FarxigaDapagliflozin Propanediol26$30,337
BrilintaTicagrelor34$26,165
Metoprolol Succinate338$8,802
Atorvastatin Calcium297$5,655
Rosuvastatin Calcium208$5,236
Ezetimibe128$5,013
Ranolazine ErRanolazine46$3,850
Losartan Potassium165$2,995
Isosorbide Mononitrate ErIsosorbide Mononitrate126$2,676
ClopidogrelClopidogrel Bisulfate146$2,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$273$281,706231 claims
NovartisEntresto$968$96,15883 claims
AstraZenecaFarxiga, Brilinta$420$56,50260 claims
Johnson & JohnsonXarelto$617$51,68156 claims
Boehringer IngelheimJardiance$339$43,19540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.

Other medical in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →